{"id":494119,"date":"2021-05-17T08:06:04","date_gmt":"2021-05-17T12:06:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/"},"modified":"2021-05-17T08:06:04","modified_gmt":"2021-05-17T12:06:04","slug":"x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/","title":{"rendered":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, May  17, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ih8S8430UbD4Ah90vuPBUO1JcsIctEsuwPmBFTSVI8nSAanD03-uF3GOdM2tmSJytetBRPnsK3cFE7-DYHS8MxfmtHusongkDva9Brop5YQ=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>X4 Pharmaceuticals, Inc.<\/strong><\/a> (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare &amp; Orphan Disease Summit.<\/p>\n<p>\n        <strong>Details are as follows:<\/strong>\n      <\/p>\n<p>\n        <strong>Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit <\/strong><br \/>\n        <br \/>Date: Thursday, May 20, 2021<br \/>Time: 2:00 PM ET<\/p>\n<p>\n        <strong>Conference: Oppenheimer Rare &amp; Orphan Disease Summit<\/strong><br \/>\n        <br \/>Date: Friday, May 21, 2021<br \/>Time: 12:25 PM ET<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dBq4Jv-u-EPauu-YnU8lK9kKvKEQ3oUHP7Pm79O9dbxTZuI_A_heI1iO4nLMhXU97QCSE3j8QGkzOMzQX2Ck7VVNAVIy9rBqk_a-JAp3je9va4yl6iE2IyxzQlKFxM7kJwBwYOVE5F9twu0hsPgOIA==\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em>Presentation Webcast Link<\/em><\/strong><\/a><\/p>\n<p>A live webcast of the Oppenheimer Rare &amp; Orphan Disease Summit presentation will be available on the investor section of the X4 Pharmaceuticals website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=REHPfhALofjr1he-LwGxukySv0GPjsqW06tzU2kYwOyB5_1OpExg_S363mZvhX-HoTT7iTNWNwkMNRxLZt2ufw==\" rel=\"nofollow noopener\" target=\"_blank\">www.x4pharma.com<\/a>. Following the live webcast, the event will remain archived on the X4 Pharmaceuticals\u2019 website for approximately 90 days.<\/p>\n<p>\n        <strong>About X4 Pharmaceuticals<\/strong><br \/>\n        <br \/>X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company\u2019s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials \u2013 in combination with ibrutinib in patients with Waldenstr\u00f6m\u2019s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=REHPfhALofjr1he-LwGxujgjsdohJW27GbFf3BPOvKAIXSkE45jUqkTpIXPbg-QEJa49yV_djVhT9-mAkazv_A==\" rel=\"nofollow noopener\" target=\"_blank\">www.x4pharma.com<\/a>.<\/p>\n<p>\n        <strong>Investors and Media:\u00a0<\/strong><br \/>\n        <br \/>Daniel Ferry<br \/>Managing Director <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PwHKGzjdR0GGILqbClC4Gmw1rsOadPb2jjboR4DOWhMB_dB5NlhrXXI0L1dtTplKLXxNFljAjUUCdLRxfLR1QGfO8mXMyYUxmZkf5ig4U9Au4Ceet4N0pDtPd27rjE6N\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>(617) 430-7576<\/p>\n<p>M\u00f3nica Rouco Molina<br \/>Senior Account Executive <br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y-8ePcO1GrhBJIJlmHqYQZc0bmXqwjyFCkJR0JNyHIPKeLNRwkQirJDemOWo1XreHJVvJJez-JreV_RmewfZmf5RT2KO62CUf9oPmdrCpRPjb3PJrIgoNFKfHqyxZ46v\" rel=\"nofollow noopener\" target=\"_blank\">mroucomolina@lifescicomms.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d455bd8a-b0a5-4b92-a26d-d610e4396d5c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 17, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare &amp; Orphan Disease Summit. Details are as follows: Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit Date: Thursday, May 20, 2021Time: 2:00 PM ET Conference: Oppenheimer Rare &amp; Orphan Disease Summit Date: Friday, May 21, 2021Time: 12:25 PM ETPresentation Webcast Link A live webcast of the Oppenheimer Rare &amp; Orphan Disease Summit presentation will be available on the investor section of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-494119","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 17, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare &amp; Orphan Disease Summit. Details are as follows: Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit Date: Thursday, May 20, 2021Time: 2:00 PM ET Conference: Oppenheimer Rare &amp; Orphan Disease Summit Date: Friday, May 21, 2021Time: 12:25 PM ETPresentation Webcast Link A live webcast of the Oppenheimer Rare &amp; Orphan Disease Summit presentation will be available on the investor section of &hellip; Continue reading &quot;X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-17T12:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences\",\"datePublished\":\"2021-05-17T12:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/\"},\"wordCount\":368,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/\",\"name\":\"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\",\"datePublished\":\"2021-05-17T12:06:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk","og_description":"BOSTON, May 17, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare &amp; Orphan Disease Summit. Details are as follows: Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit Date: Thursday, May 20, 2021Time: 2:00 PM ET Conference: Oppenheimer Rare &amp; Orphan Disease Summit Date: Friday, May 21, 2021Time: 12:25 PM ETPresentation Webcast Link A live webcast of the Oppenheimer Rare &amp; Orphan Disease Summit presentation will be available on the investor section of &hellip; Continue reading \"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-17T12:06:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences","datePublished":"2021-05-17T12:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/"},"wordCount":368,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/","name":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==","datePublished":"2021-05-17T12:06:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNzAxOCM0MTg1NDU4IzUwMDA3MjE4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-two-may-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=494119"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494119\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=494119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=494119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=494119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}